Biogen and Bio-Thera Solutions have announced positive Phase III data for the pair’s BIIB800/BAT1806 proposed rival to Roche’s Actemra/RoAcetmra (tocilizumab) anti-IL-6 receptor treatment.
The biosimilar is being developed under an agreement struck between the two firms early last year (see sidebar).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?